Literature DB >> 17172473

Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.

Ryuji Fukuzawa1, Rosemary W Heathcott, Helen E More, Anthony E Reeve.   

Abstract

BACKGROUND: Intralobar nephrogenic rests (ILNRs) are precursor lesions for Wilms tumours and are associated with WT1 gene mutations. ILNR-associated Wilms tumours have a co-clustering of WT1 and beta-catenin (CTNNB1) mutations and unique histological features characterised by a stromal-predominant histology. AIM: To determine the order in which WT1 and CTNNB1 mutations occur to understand the ILNR-Wilms tumour sequence.
METHODS: Of nine Wilms tumours with WT1 and CTNNB1 mutations, three ILNRs lesions in two Wilms tumours were available for analysis of WT1 and CTNNB1 mutations using microdissection. Immunohistochemistry was also performed to investigate how the mutations in beta-catenin alter the localisation in Wilms tumour development.
RESULTS: WT1 mutations were present in the ILNRs, however CTNNB1 mutations were absent. Immunohistochemistry for WT1 confirmed inactivation of WT1 in both ILNRs and Wilms tumours. Both the ILNRs and the associated Wilms tumours had similar immunostaining patterns for beta-catenin in the blastemal and epithelial components. Although rhabdomyoblasts were not included in ILNRs, the associated Wilms tumours showed rhabdomyogenic differentiation with a positive beta-catenin nuclear staining.
CONCLUSIONS: The results suggest that CTNNB1 mutation is a later event in Wilms tumourigenesis. CTNNB1 mutations might be associated with rhabdomyogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172473      PMCID: PMC1972432          DOI: 10.1136/jcp.2006.043083

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Allelotyping nephrogenic rests: putative precursor lesions of Wilms tumors.

Authors:  A Maitra; S Salahuddin; C F Timmons; A F Gazdar
Journal:  Pediatr Dev Pathol       Date:  1999 Sep-Oct

2.  Wnt signaling in human development: beta-catenin nuclear translocation in fetal lung, kidney, placenta, capillaries, adrenal, and cartilage.

Authors:  C G Eberhart; P Argani
Journal:  Pediatr Dev Pathol       Date:  2001 Jul-Aug

3.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 4.  Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations.

Authors:  J B Beckwith
Journal:  Am J Med Genet       Date:  1998-10-02

5.  Frequent association of beta-catenin and WT1 mutations in Wilms tumors.

Authors:  S Maiti; R Alam; C I Amos; V Huff
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

Review 6.  Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor.

Authors:  J B Beckwith; N B Kiviat; J F Bonadio
Journal:  Pediatr Pathol       Date:  1990

7.  Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.

Authors:  S Park; A Bernard; K E Bove; D A Sens; D J Hazen-Martin; A J Garvin; D A Haber
Journal:  Nat Genet       Date:  1993-12       Impact factor: 38.330

8.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 9.  Precursor lesions of Wilms tumor: clinical and biological implications.

Authors:  J B Beckwith
Journal:  Med Pediatr Oncol       Date:  1993

10.  Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.

Authors:  Ryuji Fukuzawa; Rosemary W Heathcott; Makoto Sano; Ian M Morison; Kankatsu Yun; Anthony E Reeve
Journal:  Pediatr Dev Pathol       Date:  2004-03-04
  10 in total
  22 in total

1.  Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.

Authors:  Raisa Vuononvirta; Neil J Sebire; Anthony R Dallosso; Jorge S Reis-Filho; Richard D Williams; Alan Mackay; Kerry Fenwick; Anita Grigoriadis; Alan Ashworth; Kathy Pritchard-Jones; Keith W Brown; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 2.  Wilms' tumour: a complex enigma to decipher.

Authors:  María José Robles-Frías; Michele Biscuola; María Angeles Castilla; María Angeles López-García; Felicia Sánchez-Gallego; José Palacios
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

3.  Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells.

Authors:  Murielle M Akpa; Diana Iglesias; LeeLee Chu; Antonin Thiébaut; Ida Jentoft; Leah Hammond; Elena Torban; Paul R Goodyer
Journal:  J Biol Chem       Date:  2015-12-10       Impact factor: 5.157

Review 4.  Priming the renal progenitor cell.

Authors:  Diana M Iglesias; Murielle M Akpa; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

5.  Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.

Authors:  Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

6.  Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene.

Authors:  Murielle M Akpa; Diana M Iglesias; Lee Lee Chu; Marta Cybulsky; Cristina Bravi; Paul R Goodyer
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

7.  A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway.

Authors:  Myoung Shin Kim; Seung Kew Yoon; Frank Bollig; Jirouta Kitagaki; Wonhee Hur; Nathan J Whye; Yun-Ping Wu; Miguel N Rivera; Jik Young Park; Ho-Shik Kim; Karim Malik; Daphne W Bell; Christoph Englert; Alan O Perantoni; Sean Bong Lee
Journal:  J Biol Chem       Date:  2010-03-10       Impact factor: 5.157

8.  Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus.

Authors:  Reyhan El-Kares; Pierre-Alain Hueber; Miriam Blumenkrantz; Diana Iglesias; Kim Ma; Nada Jabado; Daniel G Bichet; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2009-03-18       Impact factor: 3.714

9.  Wilms' tumor 1 gene (WT1) is overexpressed and provides an oncogenic function in pediatric nephroblastomas harboring the wild-type WT1.

Authors:  Surasak Sangkhathat; Samornmas Kanngurn; Welawee Chaiyapan; Podchanaporn Gridist; Wanwisa Maneechay
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

10.  Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.

Authors:  Anthony R Dallosso; Anne L Hancock; Marianna Szemes; Kim Moorwood; Laxmi Chilukamarri; Hsin-Hao Tsai; Abby Sarkar; Jonathan Barasch; Raisa Vuononvirta; Chris Jones; Kathy Pritchard-Jones; Brigitte Royer-Pokora; Sean Bong Lee; Ceris Owen; Sally Malik; Yi Feng; Marcus Frank; Andrew Ward; Keith W Brown; Karim Malik
Journal:  PLoS Genet       Date:  2009-11-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.